<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="35bf62a6-b5a0-9582-e063-6394a90a1b92"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use Tetracaine Hydrochloride Ophthalmic Solution 0.5% STERI‑UNIT 
 <sup>®</sup>safely and effectively. See full prescribing information for Tetracaine Hydrochloride Ophthalmic Solution.
 <br/>
      <br/>
Tetracaine Hydrochloride Ophthalmic Solution 0.5% STERI‑UNIT 
 <sup>®</sup>,
 <br/>
for topical ophthalmic use
 <br/>
Initial U.S. Approval: 1965
</title>
   <effectiveTime value="20250522"/>
   <setId root="01fba5f8-a60a-444c-9abd-299540b8815a"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="829572556"/>
            <name>REMEDYREPACK INC.</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="35bf6977-622e-78f0-e063-6294a90a2321"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250522"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70518-4183" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Tetracaine Hydrochloride</name>
                        <formCode code="C42986" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tetracaine hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="0065-0741" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4550K0SC9B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM ACETATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q40Q9N063P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ACETIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5NF5D4OPCI" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TETRACAINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="0619F35CGV" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TETRACAINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="4" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70518-4183-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43171" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, DROPPER"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="12" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70518-4183-0" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240924"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA208135" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240924"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_43BECB4C-C86C-ED3F-04CB-EDBD2519B491">
               <id root="2306db41-0558-7bb1-e063-6394a90afa28"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Tetracaine Hydrochloride Ophthalmic Solution 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic.</paragraph>
               </text>
               <effectiveTime value="20240926"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tetracaine Hydrochloride Ophthalmic Solution 0.5% is an ester local anesthetic indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. (
 
    <linkHtml href="#ID_43BECB4C-C86C-ED3F-04CB-EDBD2519B491">1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_CADE9388-DBF8-9C96-5C46-6DA09F357C2C">
               <id root="2306db41-0559-7bb1-e063-6394a90afa28"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20240926"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>One drop topically in the eye(s) as needed. Discard unused portion. (
 
    <linkHtml href="#ID_4f0d6507-88b3-7a5b-1542-9be2a8ecf2b7">2.1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_4f0d6507-88b3-7a5b-1542-9be2a8ecf2b7">
                     <id root="2306db41-055a-7bb1-e063-6394a90afa28"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Topical Administration</title>
                     <text>
                        <paragraph>One drop topically in the eye as needed.  Discard unused portion.</paragraph>
                     </text>
                     <effectiveTime value="20240926"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_23ddd2b7-ad72-9b62-6050-01dcb67974bc">
                     <id root="2306db41-055b-7bb1-e063-6394a90afa28"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Sterile Field Administration</title>
                     <text>
                        <paragraph>Open package using standard aseptic technique.  The DROP‑TAINER
 
  <sup>®</sup>dispenser may then be allowed to fall upon a sterile surface.  The entire outer surface of the DROP‑TAINER
 
  <sup>®</sup>dispenser and its contents are sterile.

 </paragraph>
                     </text>
                     <effectiveTime value="20240926"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_53765b38-f141-f0e7-07fe-96c993ca75df">
               <id root="2306db41-055c-7bb1-e063-6394a90afa28"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Sterile ophthalmic solution containing 0.5% w/v tetracaine hydrochloride equivalent to tetracaine 0.44% w/v.</paragraph>
               </text>
               <effectiveTime value="20240926"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Sterile ophthalmic solution containing 0.5% tetracaine hydrochloride (
 
    <linkHtml href="#ID_53765b38-f141-f0e7-07fe-96c993ca75df">3</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_0E34950F-20FB-D63A-A042-672E7B0EB786">
               <id root="2306db41-055d-7bb1-e063-6394a90afa28"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20240926"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None (
 
    <linkHtml href="#ID_0E34950F-20FB-D63A-A042-672E7B0EB786">4</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_995848c4-dfaf-4e48-ba68-27d56e0eb322">
               <id root="2306db41-055e-7bb1-e063-6394a90afa28"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20240926"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Warnings and Precautions (
 
    <linkHtml href="#ID_1aa8be55-8694-4120-b60c-3e77325bb638">5.4</linkHtml>)                                                                                                                2/2022 
    <br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_054fa4d7-9fb0-4860-8de1-2edb4703f84b">
               <id root="2306db41-055f-7bb1-e063-6394a90afa28"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20240926"/>
            </section>
         </component>
         <component>
            <section ID="ID_36d0b161-5041-5e24-b545-bed82db63eb8">
               <id root="2306db41-0560-7bb1-e063-6394a90afa28"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20240926"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Do not use intracamerally since use may damage corneal endothelial cells (
  
     <linkHtml href="#ID_f52040df-9231-9ca2-de12-2eb46ad2c07d">5.1</linkHtml>)
 
    </item>
                           <item>Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage. (
  
     <linkHtml href="#ID_703e7d76-acbe-7e04-3347-4ee786d18fbd">5.2</linkHtml>)
 
    </item>
                           <item>Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye. (
  
     <linkHtml href="#ID_b4b2ee6a-3a39-d512-6d72-f13e242b8e76">5.3</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">For Administration by Healthcare Provider:</content>Tetracaine Hydrochloride Ophthalmic Solution 0.5% is not intended for patient self-administration. (
  
     <linkHtml href="#ID_1aa8be55-8694-4120-b60c-3e77325bb638">5.4</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_f52040df-9231-9ca2-de12-2eb46ad2c07d">
                     <id root="2306db41-0561-7bb1-e063-6394a90afa28"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Corneal injury with Intracameral Use</title>
                     <text>
                        <paragraph>Not for injection or intraocular use. Do not use intracamerally because use of TetracaineHydrochloride Ophthalmic Solution 0.5% may lead to damage of the corneal endothelial cells.</paragraph>
                     </text>
                     <effectiveTime value="20240926"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_703e7d76-acbe-7e04-3347-4ee786d18fbd">
                     <id root="2306db41-0562-7bb1-e063-6394a90afa28"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Corneal Toxicity</title>
                     <text>
                        <paragraph>Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage.</paragraph>
                     </text>
                     <effectiveTime value="20240926"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b4b2ee6a-3a39-d512-6d72-f13e242b8e76">
                     <id root="2306db41-0563-7bb1-e063-6394a90afa28"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Corneal Injury due to Insensitivity</title>
                     <text>
                        <paragraph>Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye.</paragraph>
                     </text>
                     <effectiveTime value="20240926"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1aa8be55-8694-4120-b60c-3e77325bb638">
                     <id root="2306db41-0564-7bb1-e063-6394a90afa28"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 For Administration by Healthcare Provider</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Tetracaine Hydrochloride Ophthalmic Solution 0.5% is indicated for administration under the direct supervision of a healthcare provider. Tetracaine Hydrochloride Ophthalmic Solution 0.5% is not intended for patient self-administration [
 
   <content styleCode="italics">see Warnings and Precautions (
  
    <linkHtml href="#ID_703e7d76-acbe-7e04-3347-4ee786d18fbd">5.2</linkHtml>
                              </content>)].

  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240926"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_B8477333-170F-DD5F-8783-8315ED36DB76">
               <id root="2306db41-0565-7bb1-e063-6394a90afa28"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious ocular adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>Corneal injury with Intracameral Use
  
   <content styleCode="italics">[See
   
    <linkHtml href="#ID_f52040df-9231-9ca2-de12-2eb46ad2c07d">Warnings and Precautions (5.1)</linkHtml>]
  
   </content>
                     </item>
                     <item>Corneal Toxicity
  
   <content styleCode="italics">[See
   
    <linkHtml href="#ID_703e7d76-acbe-7e04-3347-4ee786d18fbd">Warnings and Precautions (5.2)</linkHtml>]
  
   </content>
                     </item>
                     <item>Corneal Injury due to Insensitivity
  
   <content styleCode="italics">[
   
    <linkHtml href="#ID_b4b2ee6a-3a39-d512-6d72-f13e242b8e76">See Warnings and Precautions (5.3)</linkHtml>]
  
   </content>
                     </item>
                  </list>
                  <paragraph>The following adverse reactions have been identified following use of Tetracaine Hydrochloride Ophthalmic Solution 0.5%.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Ocular Adverse Reactions</content>
                     <br/>  Transient stinging, burning, and conjunctival redness, eye irritation, eye pain, ocular discomfort.

 </paragraph>
               </text>
               <effectiveTime value="20240926"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ocular adverse events: stinging, burning, conjunctival redness (
 
    <linkHtml href="#ID_B8477333-170F-DD5F-8783-8315ED36DB76">6</linkHtml>)

   </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>  To report SUSPECTED ADVERSE REACTIONS, contact Alcon Laboratories, Inc., at 1-800-757-9195 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 
     <br/>
                           </content>
                           <br/>   

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_e3057d1d-f321-ba99-cdfa-91788c52fd3a">
               <id root="2306db41-0566-7bb1-e063-6394a90afa28"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20240926"/>
               <component>
                  <section ID="ID_ff092156-47ab-4d3e-83c5-24c95a9a79f9">
                     <id root="2306db41-0567-7bb1-e063-6394a90afa28"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary 
   <br/>
                           </content>There are no adequate and well-controlled studies with Tetracaine Hydrochloride Ophthalmic Solution 0.5% in pregnant women.  Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature.

 </paragraph>
                     </text>
                     <effectiveTime value="20240926"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_464a4a61-4e89-3a09-7c4a-759024868923">
                     <id root="2306db41-0568-7bb1-e063-6394a90afa28"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary 
   <br/>
                           </content>There are no data to assess whether Tetracaine Hydrochloride Ophthalmic Solution 0.5% is excreted in human milk or to assess its effects on milk production/excretion.  The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Tetracaine Hydrochloride Ophthalmic Solution 0.5% and any potential adverse effects on the breastfed child from Tetracaine Hydrochloride Ophthalmic Solution 0.5% or from the underlying maternal condition.

 </paragraph>
                     </text>
                     <effectiveTime value="20240926"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_dfb88137-d6c0-db4a-1cac-947d8a7623ce">
                     <id root="2306db41-0569-7bb1-e063-6394a90afa28"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>No human data on the effect of Tetracaine Hydrochloride Ophthalmic Solution 0.5% on fertility are available.</paragraph>
                     </text>
                     <effectiveTime value="20240926"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_12b30a1e-3daa-b716-6166-ddbbc14e4497">
                     <id root="2306db41-056a-7bb1-e063-6394a90afa28"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety in the pediatric population has been demonstrated in clinical trials.  Efficacy of tetracaine hydrochloride ophthalmic solution for use in pediatric patients has been extrapolated from adequate and well controlled clinical trials in the adult population.</paragraph>
                     </text>
                     <effectiveTime value="20240926"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_5fbc860e-eb74-b4f2-9366-83a8b751d36a">
                     <id root="2306db41-056b-7bb1-e063-6394a90afa28"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>No overall differences in safety or effectiveness of tetracaine hydrochloride ophthalmic solution have been observed between elderly and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20240926"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a5a42578-8546-3eef-e54b-8467ba17a295">
               <id root="2306db41-056c-7bb1-e063-6394a90afa28"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Prolonged use of a topical ocular anesthetic including TetracaineHydrochloride Ophthalmic Solution 0.5% may produce permanent corneal opacification and ulceration with accompanying visual loss.  Symptoms related to systemic toxicity consist mainly of effects on the neurologic and cardiovascular systems.</paragraph>
               </text>
               <effectiveTime value="20240926"/>
            </section>
         </component>
         <component>
            <section ID="ID_52C08E15-7A1A-59B3-A388-5AEA96F4791C">
               <id root="2306db41-056d-7bb1-e063-6394a90afa28"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Tetracaine hydrochloride is chemically designated as benzoic acid, 4-(butylamino)-,2-(dimethylamino) ethyl ester, monohydrochloride.  Its chemical formula is C
 
  <sub>15</sub>H
 
  <sub>24</sub>N
 
  <sub>2</sub>O
 
  <sub>2</sub>• HCl and it is represented by the chemical structure:

 </paragraph>
                  <renderMultiMedia referencedObject="MM46913"/>
                  <paragraph>Tetracaine hydrochloride is a fine, white, crystalline, odorless powder and has a molecular weight of 300.82.  Tetracaine Hydrochloride Ophthalmic Solution 0.5% has a pH of 3.7 to 5.5.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Active ingredient:</content>tetracaine hydrochloride 0.5% w/v (equivalent to 0.44% w/v tetracaine)

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive ingredients:</content>sodium chloride, sodium acetate trihydrate, acetic acid (to adjust pH approximately 4.5), Water for Injection, USP

 </paragraph>
               </text>
               <effectiveTime value="20240926"/>
               <component>
                  <observationMedia ID="MM46913">
                     <text>Chemical Diagram</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="chemical.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_C78E3824-0D66-90FA-EE83-B01855B89105">
               <id root="2306db41-056e-7bb1-e063-6394a90afa28"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text/>
               <effectiveTime value="20240926"/>
               <component>
                  <section ID="ID_98da6196-d8c1-15ec-70e4-07d83a15d782">
                     <id root="2306db41-056f-7bb1-e063-6394a90afa28"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia.</paragraph>
                     </text>
                     <effectiveTime value="20240926"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_01f2206e-e86b-18b9-961f-e8ac7a7c7d44">
                     <id root="2306db41-0570-7bb1-e063-6394a90afa28"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The systemic exposure to tetracaine following topical ocular administration of Tetracaine Hydrochloride Ophthalmic Solution 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues.</paragraph>
                     </text>
                     <effectiveTime value="20240926"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_8460eb23-5c87-ff01-454d-a0000dff603d">
               <id root="2306db41-0571-7bb1-e063-6394a90afa28"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text/>
               <effectiveTime value="20240926"/>
               <component>
                  <section ID="ID_49f44c23-cb85-9b57-b616-6d3aa14cc8be">
                     <id root="2306db41-0572-7bb1-e063-6394a90afa28"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature.  Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride.</paragraph>
                        <paragraph>Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature.</paragraph>
                     </text>
                     <effectiveTime value="20240926"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_095f4969-9e62-ef87-7083-9fe0373002a2">
               <id root="2306db41-0573-7bb1-e063-6394a90afa28"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>Topical administration of tetracainehydrochloride ophthalmic solution results in localized temporary anesthesia.  The maximum effect is achieved within 10–20 seconds after instillation, with efficacy lasting 10–20 minutes.  Duration of effect can be extended with repeated dosing.
 
  <content styleCode="italics">[see
  
   <linkHtml href="#ID_703e7d76-acbe-7e04-3347-4ee786d18fbd">Corneal toxicity (5.2)</linkHtml>and
  
   <linkHtml href="#ID_a5a42578-8546-3eef-e54b-8467ba17a295">Overdosage (10)</linkHtml>]
 
  </content>.

 </paragraph>
               </text>
               <effectiveTime value="20240926"/>
            </section>
         </component>
         <component>
            <section ID="ID_1EB7CD70-06D7-F1B3-6637-B6973BC65D44">
               <id root="2306db41-0574-7bb1-e063-6394a90afa28"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Tetracaine Hydrochloride Ophthalmic Solution 0.5% STERI-UNITS® is supplied as single patient use, 4 mL filled in 4-mL natural medium- or low-density polyethylene plastic DROP-TAINER® dispensers and natural low-density polyethylene tips with white polypropylene caps in a carton of 12.  Each sterilized DROP-TAINER® dispenser is packaged in a clear PVC and Tyvek blister.  This product does not contain a preservative; discard unused portion.</paragraph>
                  <paragraph>NDC: 70518-4183-00</paragraph>
                  <paragraph>NDC: 70518-4183-01</paragraph>
                  <paragraph>PACKAGING: 12 in 2 CARTON</paragraph>
                  <paragraph>PACKAGING: 1-4 mL BOTTLE, DROPPER TYPE 0</paragraph>
                  <paragraph/>
                  <paragraph>Storage: Store at 2°C to 25°C (36°F to 77°F). Protect from light. Do not use if solution contains crystals, is cloudy, or discolored.</paragraph>
                  <paragraph/>
                  <paragraph>Repackaged and Distributed By:</paragraph>
                  <paragraph>Remedy Repack, Inc.</paragraph>
                  <paragraph>625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20240926"/>
            </section>
         </component>
         <component>
            <section ID="ID_fbce2c31-9d0e-bba8-24dc-5b613bf7284e">
               <id root="2306d22e-7f19-2cc6-e063-6394a90afe3f"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Eye Care Precaution </content>
                     <br/>
Advise patients that, due to the effect of the anesthetic, their eyes will be insensitive up to 20 minutes and that care should be taken to avoid accidental injuries.
 </paragraph>
                  <paragraph/>
                  <paragraph>Repackaged By / Distributed By: RemedyRepack Inc.</paragraph>
                  <paragraph>625 Kolter Drive, Indiana, PA 15701</paragraph>
                  <paragraph>(724) 465-8762</paragraph>
               </text>
               <effectiveTime value="20240926"/>
            </section>
         </component>
         <component>
            <section ID="id_link_2306c241-7a22-eaa6-e063-6394a90ac0b0">
               <id root="35bf7532-c629-8382-e063-6294a90ab0e2"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>DRUG: Tetracaine Hydrochloride</paragraph>
                  <paragraph>GENERIC: tetracaine hydrochloride</paragraph>
                  <paragraph>DOSAGE: SOLUTION</paragraph>
                  <paragraph>ADMINSTRATION: OPHTHALMIC</paragraph>
                  <paragraph>NDC: 70518-4183-0</paragraph>
                  <paragraph>NDC: 70518-4183-1</paragraph>
                  <paragraph>PACKAGING: 4 mL in 1 BOTTLE, DROPPER</paragraph>
                  <paragraph>OUTER PACKAGING: 12 in 1 CARTON</paragraph>
                  <paragraph>ACTIVE INGREDIENT(S):</paragraph>
                  <list listType="unordered">
                     <item>Tetracaine Hydrochloride 5mg in 1mL</item>
                  </list>
                  <paragraph>INACTIVE INGREDIENT(S):</paragraph>
                  <list listType="unordered">
                     <item>Sodium Chloride</item>
                     <item>Sodium Acetate</item>
                     <item>Acetic Acid</item>
                     <item>Water</item>
                  </list>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_35bf7433-3abc-61ab-e063-6394a90a82d0"/>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_35bef2dc-d447-d000-e063-6294a90af3df"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20240926"/>
               <component>
                  <observationMedia ID="img_35bf7433-3abc-61ab-e063-6394a90a82d0">
                     <text>MM1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Tetracaine Hydrochloride 0.5_70518-4183-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_35bef2dc-d447-d000-e063-6294a90af3df">
                     <text>MM2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Tetracaine Hydrochloride 0.5_70518-4183-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>